{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T15:02:54Z","timestamp":1790953374728,"version":"4.1.0"},"reference-count":165,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bayer AG, Wuppertal, Germany"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite recent advances in pharmacological treatment, chronic heart failure (HF) is associated with significant morbidity and mortality, and further treatment options are needed. Intact nitric oxide (NO)\u2013soluble guanylyl cyclase (sGC)\u2013cyclic guanosine monophosphate (cGMP) signalling is a prerequisite of cardiovascular health. cGMP produced by NO\/NO\u2013sGC acts as a second messenger molecule via various downstream targets, which influence a broad spectrum of critical physiological parameters. Impairment of this cascade in the cardiovascular system is considered an important pathomechanism in HF.<\/jats:p>\n                  <jats:p>This review examines pharmacological therapies that act through the NO\u2013sGC\u2013cGMP signalling pathway. We will focus on the molecular mode(s) of action of NO-independent but haem-dependent sGC stimulators, and will examine evidence from preclinical studies demonstrating cardiovascular benefits of these therapies and their increasing number of effects on other susceptible tissues and organs, which together could contribute to clinical outcomes in HF.<\/jats:p>\n                  <jats:p>The sGC stimulator vericiguat may be considered, in addition to standard therapy, for adults with symptomatic HF with reduced ejection fraction following a worsening event. The findings from pivotal clinical trials that led to these recommendations will be outlined and classified in terms of their significance for different subpopulations. These include the Phase 3 VICTORIA and VICTOR trials. Finally, further research areas and ongoing studies designed to address existing gaps in our knowledge regarding vericiguat and related drugs will be highlighted.<\/jats:p>","DOI":"10.1093\/eschf\/xvag117","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T11:42:39Z","timestamp":1777030959000},"source":"Crossref","is-referenced-by-count":0,"title":["Use of soluble guanylyl cyclase stimulators in heart failure therapy\u2014a mode of action perspective"],"prefix":"10.1093","volume":"13","author":[{"given":"Frank","family":"Ruschitzka","sequence":"first","affiliation":[{"name":"Department of Cardiology, University Heart Center, University Hospital Zurich and University of Zurich , Zurich ,","place":["Switzerland"]},{"name":"Department of Cardiology, Center for Translational and Experimental Cardiology (CTEC), University Hospital Zurich, University of Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4564-3574","authenticated-orcid":false,"given":"Robert","family":"Lukowski","sequence":"additional","affiliation":[{"name":"Institute of Pharmacy, Pharmacology, Toxicology and Clinical Pharmacy, University of Tu\u0308bingen , T\u00fcbingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Corda","sequence":"additional","affiliation":[{"name":"BCC AG, Pharmaceuticals, Bayer Consumer Care AG , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Meier","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Bayer AG , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sandner","sequence":"additional","affiliation":[{"name":"Research & Early Development, Bayer AG, Pharmaceuticals, Aprather Weg 18a, 42113 Wuppertal, Germany & Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"2026051407243720500_xvag117-B1","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026051407243720500_xvag117-B2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12154924","article-title":"Heart failure prevalence rates and its association with other cardiovascular diseases and chronic kidney disease: SIMETAP-HF study","volume":"12","author":"Ruiz-Garcia","year":"2023","journal-title":"J Clin Med"},{"key":"2026051407243720500_xvag117-B3","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1002\/ehf2.14321","article-title":"Trends in heart failure prevalence in Japan 2014-2019: a report from healthcare administration databases","volume":"10","author":"Zhang","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026051407243720500_xvag117-B4","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/s12872-023-03337-1","article-title":"Incidence and prevalence of heart failure in England: a descriptive analysis of linked primary and secondary care data\u2014the PULSE study","volume":"23","author":"Bellanca","year":"2023","journal-title":"BMC Cardiovasc Disord"},{"key":"2026051407243720500_xvag117-B5","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026051407243720500_xvag117-B6","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2026051407243720500_xvag117-B7","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/cir.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2026051407243720500_xvag117-B8","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/cvr\/cvaa217","article-title":"Metabolic inflammation in heart failure with preserved ejection fraction","volume":"117","author":"Schiattarella","year":"2021","journal-title":"Cardiovasc Res"},{"key":"2026051407243720500_xvag117-B9","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026051407243720500_xvag117-B10","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026051407243720500_xvag117-B11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10741-012-9323-1","article-title":"Soluble guanylate cyclase: a potential therapeutic target for heart failure","volume":"18","author":"Gheorghiade","year":"2013","journal-title":"Heart Fail Rev"},{"key":"2026051407243720500_xvag117-B12","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000536","article-title":"The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction","volume":"2","author":"Greene","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"2026051407243720500_xvag117-B13","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1161\/circulationaha.110.981738","article-title":"Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease","volume":"123","author":"Stasch","year":"2011","journal-title":"Circulation"},{"key":"2026051407243720500_xvag117-B14","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1161\/ATVBAHA.109.199893","article-title":"Reduced NO-cGMP signaling contributes to vascular inflammation and insulin resistance induced by high-fat feeding","volume":"30","author":"Rizzo","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026051407243720500_xvag117-B15","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1172\/jci119883","article-title":"Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts","volume":"101","author":"Calderone","year":"1998","journal-title":"J Clin Invest"},{"key":"2026051407243720500_xvag117-B16","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1161\/01.cir.98.22.2365","article-title":"Nobel prize awarded to scientists for nitric oxide discoveries","volume":"98","author":"SoRelle","year":"1998","journal-title":"Circulation"},{"key":"2026051407243720500_xvag117-B17","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1161\/CIRCULATIONAHA.123.065517","article-title":"Metabolic communication by SGLT2 inhibition","volume":"149","author":"Billing","year":"2024","journal-title":"Circulation"},{"key":"2026051407243720500_xvag117-B18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12933-019-0914-1","article-title":"Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction","volume":"18","author":"Zhang","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"2026051407243720500_xvag117-B19","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.ijcard.2014.01.102","article-title":"PDE5 inhibitor sildenafil in the treatment of heart failure: a meta-analysis of randomized controlled trials","volume":"172","author":"Zhuang","year":"2014","journal-title":"Int J Cardiol"},{"key":"2026051407243720500_xvag117-B20","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12872-017-0576-4","article-title":"Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials","volume":"17","author":"Hwang","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"2026051407243720500_xvag117-B21","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/ejhf.662","article-title":"Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension","volume":"19","author":"Liu","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026051407243720500_xvag117-B22","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial","volume":"309","author":"Redfield","year":"2013","journal-title":"JAMA"},{"key":"2026051407243720500_xvag117-B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0204610","article-title":"Pulmonary hypertension-targeted therapies in heart failure: a systematic review and meta-analysis","volume":"13","author":"Guay","year":"2018","journal-title":"PLoS One"},{"key":"2026051407243720500_xvag117-B24","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.115.002729","article-title":"Impaired right ventricular-pulmonary arterial coupling and effect of sildenafil in heart failure with preserved ejection fraction: an ancillary analysis from the phosphodiesterase-5 inhibition to improve clinical status and exercise capacity in diastolic heart failure (RELAX) trial","volume":"9","author":"Hussain","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2026051407243720500_xvag117-B25","author":"Food and Drug Administration"},{"key":"2026051407243720500_xvag117-B26","author":"European Medicines Agency"},{"key":"2026051407243720500_xvag117-B27","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1253\/circj.CJ-08-1102","article-title":"Endothelial function and oxidative stress in cardiovascular diseases","volume":"73","author":"Higashi","year":"2009","journal-title":"Circ J"},{"key":"2026051407243720500_xvag117-B28","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.niox.2018.05.001","article-title":"Discovery and development of sGC stimulators for the treatment of pulmonary hypertension and rare diseases","volume":"77","author":"Sandner","year":"2018","journal-title":"Nitric Oxide"},{"key":"2026051407243720500_xvag117-B29","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.niox.2018.03.019","article-title":"Genetic alterations in the NO-cGMP pathway and cardiovascular risk","volume":"76","author":"Wobst","year":"2018","journal-title":"Nitric Oxide"},{"key":"2026051407243720500_xvag117-B30","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/nature12722","article-title":"Dysfunctional nitric oxide signalling increases risk of myocardial infarction","volume":"504","author":"Erdmann","year":"2013","journal-title":"Nature"},{"key":"2026051407243720500_xvag117-B31","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1161\/circulationaha.117.028021","article-title":"Phenotypic consequences of a genetic predisposition to enhanced nitric oxide signaling","volume":"137","author":"Emdin","year":"2018","journal-title":"Circulation"},{"key":"2026051407243720500_xvag117-B32","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/nrcardio.2017.224","article-title":"Nitric oxide signalling in cardiovascular health and disease","volume":"15","author":"Farah","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"2026051407243720500_xvag117-B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.apha.2016.05.001","article-title":"The endothelium-dependent nitric oxide-cGMP pathway","volume":"77","author":"M\u00f3nica","year":"2016","journal-title":"Adv Pharmacol"},{"key":"2026051407243720500_xvag117-B34","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1089\/ars.2016.6693","article-title":"Structure and activation of soluble guanylyl cyclase, the nitric oxide sensor","volume":"26","author":"Montfort","year":"2017","journal-title":"Antioxid Redox Signal"},{"key":"2026051407243720500_xvag117-B35","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1111\/bph.15698","article-title":"Soluble GC stimulators and activators: past, present and future","volume":"181","author":"Sandner","year":"2021","journal-title":"Br J Pharmacol"},{"key":"2026051407243720500_xvag117-B36","author":"European Medicines Agency"},{"key":"2026051407243720500_xvag117-B37","author":"Akebia"},{"key":"2026051407243720500_xvag117-B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106931","article-title":"Modulation of the nitric oxide\/cGMP pathway in cardiac contraction and relaxation: potential role in heart failure treatment","volume":"196","author":"Mollace","year":"2023","journal-title":"Pharmacological Research Epub"},{"key":"2026051407243720500_xvag117-B39","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1111\/bph.15500","article-title":"Visualising and understanding cGMP signals in the cardiovascular system","volume":"179","author":"Feil","year":"2021","journal-title":"Br J Pharmacol"},{"key":"2026051407243720500_xvag117-B40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.792798","article-title":"Cyclic GMP and PKG signaling in heart failure","volume":"13","author":"Numata","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026051407243720500_xvag117-B41","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/FJC.0000000000000749","article-title":"cGMP signaling and modulation in heart failure","volume":"75","author":"Blanton","year":"2020","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026051407243720500_xvag117-B42","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/fjc.0000000000000817","article-title":"Targets of cGMP\/cGKI in cardiac myocytes","volume":"75","author":"Adler","year":"2020","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026051407243720500_xvag117-B43","doi-asserted-by":"publisher","first-page":"H672","DOI":"10.1152\/ajpheart.00198.2011","article-title":"IRAG and novel PKG targeting in the cardiovascular system","volume":"301","author":"Schlossmann","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026051407243720500_xvag117-B44","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/jcdd5010004","article-title":"Imaging of PDE2- and PDE3-mediated cGMP-to-cAMP cross-talk in cardiomyocytes","volume":"5","author":"Pavlaki","year":"2018","journal-title":"J Cardiovasc Dev Dis"},{"key":"2026051407243720500_xvag117-B45","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41569-022-00756-z","article-title":"Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure","volume":"20","author":"Kamel","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"2026051407243720500_xvag117-B46","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1111\/bph.15824","article-title":"Recent developments in cGMP research: from mechanisms to medicines and back","volume":"179","author":"Lukowski","year":"2022","journal-title":"Br J Pharmacol"},{"key":"2026051407243720500_xvag117-B47","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00395-004-0459-6","article-title":"Vascular actions of natriuretic peptides. Cyclic GMP-dependent and -independent mechanisms","volume":"99","author":"Ahluwalia","year":"2004","journal-title":"Basic Res Cardiol"},{"key":"2026051407243720500_xvag117-B48","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1146\/annurev-med-052914-091923","article-title":"New pharmacological strategies to increase cGMP","volume":"67","author":"Buglioni","year":"2016","journal-title":"Annu Rev Med"},{"key":"2026051407243720500_xvag117-B49","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1042\/BST20190225","article-title":"cGMP signalling in cardiomyocyte microdomains","volume":"47","author":"Bork","year":"2019","journal-title":"Biochem Soc Trans"},{"key":"2026051407243720500_xvag117-B50","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.yjmcc.2019.03.024","article-title":"C53: a novel particulate guanylyl cyclase B receptor activator that has sustained activity in vivo with anti-fibrotic actions in human cardiac and renal fibroblasts","volume":"130","author":"Chen","year":"2019","journal-title":"J Mol Cell Cardiol"},{"key":"2026051407243720500_xvag117-B51","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1253\/circj.CJ-17-0499","article-title":"Atrial natriuretic peptide\u2014old but new therapeutic in cardiovascular diseases","volume":"81","author":"Ichiki","year":"2017","journal-title":"Circ J"},{"key":"2026051407243720500_xvag117-B52","volume-title":"Entresto Summary of Product Characteristics","author":"European Medicines Agency","year":"2015"},{"key":"2026051407243720500_xvag117-B53","volume-title":"Entresto: Highlights of Prescribing Information","author":"Food and Drug Administration","year":"2024"},{"key":"2026051407243720500_xvag117-B54","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19041006","article-title":"Particulate guanylyl cyclase A\/cGMP signaling pathway in the kidney: physiologic and therapeutic indications","volume":"19","author":"Chen","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2026051407243720500_xvag117-B55","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00210-012-0730-6","article-title":"cGMP becomes a drug target","volume":"385","author":"Schlossmann","year":"2012","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2026051407243720500_xvag117-B56","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.niox.2018.03.020","article-title":"NO-GC in cells \u2018off the beaten track\u2019","volume":"77","author":"Friebe","year":"2018","journal-title":"Nitric Oxide"},{"key":"2026051407243720500_xvag117-B57","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1093\/cvr\/cvy039","article-title":"Cardioprotection by ischemic postconditioning and cyclic guanosine monophosphate-elevating agents involves cardiomyocyte nitric oxide-sensitive guanylyl cyclase","volume":"114","author":"Frankenreiter","year":"2018","journal-title":"Cardiovasc Res"},{"key":"2026051407243720500_xvag117-B58","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3390\/ijms19030801","article-title":"cGMP signaling in the cardiovascular system\u2014the role of compartmentation and its live cell imaging","volume":"19","author":"Bork","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2026051407243720500_xvag117-B59","doi-asserted-by":"publisher","first-page":"4696","DOI":"10.1111\/bph.14835","article-title":"Mind the gap (junction): cGMP induced by nitric oxide in cardiac myocytes originates from cardiac fibroblasts","volume":"176","author":"Menges","year":"2019","journal-title":"Br J Pharmacol"},{"key":"2026051407243720500_xvag117-B60","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1161\/circresaha.124.326070","article-title":"Cardiomyocyte GC1 mediates estrogenic angiogenesis in right heart remodeling","volume":"137","author":"Fukuma","year":"2025","journal-title":"Circ Res"},{"key":"2026051407243720500_xvag117-B61","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/164_2016_100","article-title":"Novel sGC stimulators and sGC activators for the treatment of heart failure","volume":"243","author":"Breitenstein","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"2026051407243720500_xvag117-B62","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.redox.2017.08.020","article-title":"Identification of a soluble guanylate cyclase in RBCs: preserved activity in patients with coronary artery disease","volume":"14","author":"Cortese-Krott","year":"2018","journal-title":"Redox Biol"},{"key":"2026051407243720500_xvag117-B63","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.jacbts.2023.02.017","article-title":"Stimulation of erythrocyte soluble guanylyl cyclase induces cGMP export and cardioprotection in type 2 diabetes","volume":"8","author":"Jiao","year":"2023","journal-title":"JACC Basic Transl Sci"},{"key":"2026051407243720500_xvag117-B64","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1073\/pnas.0304264101","article-title":"Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment","volume":"101","author":"Ahluwalia","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026051407243720500_xvag117-B65","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1089\/ars.2015.6542","article-title":"Decreased soluble guanylate cyclase contributes to cardiac dysfunction induced by chronic doxorubicin treatment in mice","volume":"26","author":"Vandenwijngaert","year":"2017","journal-title":"Antioxid Redox Signal"},{"key":"2026051407243720500_xvag117-B66","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/hr.2009.64","article-title":"Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart","volume":"32","author":"Masuyama","year":"2009","journal-title":"Hypertens Res"},{"key":"2026051407243720500_xvag117-B67","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1136\/annrheumdis-2013-204508","article-title":"Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFbeta signalling","volume":"74","author":"Beyer","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2026051407243720500_xvag117-B68","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00210-019-01779-z","article-title":"cGMP: a unique 2nd messenger molecule\u2014recent developments in cGMP research and development","volume":"393","author":"Friebe","year":"2020","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2026051407243720500_xvag117-B69","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/cvr\/cvn068","article-title":"Gender-specific hypertension and responsiveness to nitric oxide in sGCalpha1 knockout mice","volume":"79","author":"Buys","year":"2008","journal-title":"Cardiovasc Res"},{"key":"2026051407243720500_xvag117-B70","doi-asserted-by":"publisher","first-page":"H157","DOI":"10.1152\/ajpheart.01273.2010","article-title":"sGC\u03b11 mediates the negative inotropic effects of NO in cardiac myocytes independent of changes in calcium handling","volume":"301","author":"Cawley","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026051407243720500_xvag117-B71","doi-asserted-by":"publisher","first-page":"H1246","DOI":"10.1152\/ajpheart.00852.2013","article-title":"PDE2-mediated cAMP hydrolysis accelerates cardiac fibroblast to myofibroblast conversion and is antagonized by exogenous activation of cGMP signaling pathways","volume":"306","author":"Vettel","year":"2014","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026051407243720500_xvag117-B72","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1161\/circresaha.108.184408","article-title":"Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs","volume":"104","author":"Kr\u00fcger","year":"2009","journal-title":"Circ Res"},{"key":"2026051407243720500_xvag117-B73","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1161\/circresaha.108.193326","article-title":"Hypophosphorylation of the Stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium","volume":"104","author":"Borb\u00e9ly","year":"2009","journal-title":"Circ Res"},{"key":"2026051407243720500_xvag117-B74","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1755-1536-5-15","article-title":"Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease","volume":"5","author":"Fan","year":"2012","journal-title":"Fibrogenesis Tissue Repair"},{"key":"2026051407243720500_xvag117-B75","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1161\/circulationaha.111.076075","article-title":"Low myocardial protein kinase G activity in heart failure with preserved ejection fraction","volume":"126","author":"van Heerebeek","year":"2012","journal-title":"Circulation"},{"key":"2026051407243720500_xvag117-B76","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.tips.2014.05.003","article-title":"Turning on cGMP-dependent pathways to treat cardiac dysfunctions: boom, bust, and beyond","volume":"35","author":"Lukowski","year":"2014","journal-title":"Trends Pharmacol Sci"},{"key":"2026051407243720500_xvag117-B77","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1111\/bph.15530","article-title":"Constitutive protein kinase G activation exacerbates stress-induced cardiomyopathy","volume":"179","author":"Schwaerzer","year":"2022","journal-title":"Br J Pharmacol"},{"key":"2026051407243720500_xvag117-B78","doi-asserted-by":"publisher","first-page":"10394","DOI":"10.1074\/jbc.RA119.010984","article-title":"A substitution in cGMP-dependent protein kinase 1 associated with aortic disease induces an active conformation in the absence of cGMP","volume":"295","author":"Chan","year":"2020","journal-title":"J Biol Chem"},{"key":"2026051407243720500_xvag117-B79","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.ajhg.2013.06.019","article-title":"Recurrent gain-of-function mutation in PRKG1 causes thoracic aortic aneurysms and acute aortic dissections","volume":"93","author":"Guo","year":"2013","journal-title":"Am J Hum Genet"},{"key":"2026051407243720500_xvag117-B80","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1093\/eurheartj\/ehr445","article-title":"Stress-dependent dilated cardiomyopathy in mice with cardiomyocyte-restricted inactivation of cyclic GMP-dependent protein kinase I","volume":"34","author":"Frantz","year":"2013","journal-title":"Eur Heart J"},{"key":"2026051407243720500_xvag117-B81","doi-asserted-by":"publisher","first-page":"12925","DOI":"10.1073\/pnas.1414364111","article-title":"Roles of cGMP-dependent protein kinase I (cGKI) and PDE5 in the regulation of Ang II-induced cardiac hypertrophy and fibrosis","volume":"111","author":"Patrucco","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026051407243720500_xvag117-B82","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1042\/cs20241204","article-title":"Angiotensin II-induced cardiac fibrosis and dysfunction are exacerbated by deletion of cGKI in periostin+ myofibroblasts","volume":"139","author":"Santos","year":"2025","journal-title":"Clin Sci (Lond)"},{"key":"2026051407243720500_xvag117-B83","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.149075","article-title":"MLK3 mediates impact of PKG1\u03b1 on cardiac function and controls blood pressure through separate mechanisms","volume":"6","author":"Calamaras","year":"2021","journal-title":"JCI Insight"},{"key":"2026051407243720500_xvag117-B84","doi-asserted-by":"publisher","first-page":"16671","DOI":"10.1073\/pnas.0405509101","article-title":"Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis","volume":"101","author":"Melichar","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026051407243720500_xvag117-B85","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1113\/jphysiol.2013.270306","article-title":"Molecular mechanisms of neuronal nitric oxide synthase in cardiac function and pathophysiology","volume":"592","author":"Zhang","year":"2014","journal-title":"J Physiol"},{"key":"2026051407243720500_xvag117-B86","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.01380","article-title":"Calcium in the pathophysiology of atrial fibrillation and heart failure","volume":"9","author":"Denham","year":"2018","journal-title":"Front Physiol"},{"key":"2026051407243720500_xvag117-B87","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/circulationaha.113.006641","article-title":"Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial fibrillation","volume":"129","author":"Voigt","year":"2014","journal-title":"Circulation"},{"key":"2026051407243720500_xvag117-B88","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1161\/circulationaha.111.067306","article-title":"Enhanced sarcoplasmic reticulum Ca2+ leak and increased Na+-Ca2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation","volume":"125","author":"Voigt","year":"2012","journal-title":"Circulation"},{"key":"2026051407243720500_xvag117-B89","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1161\/circulationaha.113.006611","article-title":"Ryanodine receptor-mediated calcium leak drives progressive development of an atrial fibrillation substrate in a transgenic mouse model","volume":"129","author":"Li","year":"2014","journal-title":"Circulation"},{"key":"2026051407243720500_xvag117-B90","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1172\/jci37059","article-title":"Calmodulin kinase II-mediated sarcoplasmic reticulum Ca2+ leak promotes atrial fibrillation in mice","volume":"119","author":"Chelu","year":"2009","journal-title":"J Clin Invest"},{"key":"2026051407243720500_xvag117-B91","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1161\/circulationaha.110.981407","article-title":"Nitrate therapy: new aspects concerning molecular action and tolerance","volume":"123","author":"M\u00fcnzel","year":"2011","journal-title":"Circulation"},{"key":"2026051407243720500_xvag117-B92","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/978-3-540-68964-5_13","article-title":"NO-independent, haem-dependent soluble guanylate cyclase stimulators","volume":"191","author":"Stasch","year":"2009","journal-title":"Handb Exp Pharmacol"},{"key":"2026051407243720500_xvag117-B93","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/hh0102.102330","article-title":"Nitric oxide donors and cardiovascular agents odulating the bioactivity of nitric oxide","volume":"90","author":"Ignarro","year":"2002","journal-title":"Circ Res"},{"key":"2026051407243720500_xvag117-B94","doi-asserted-by":"publisher","first-page":"365","DOI":"10.11124\/JBISRIR-2017-003842","article-title":"Effectiveness of dietary inorganic nitrate for lowering blood pressure in hypertensive adults: a systematic review","volume":"17","author":"Remington","year":"2019","journal-title":"JBI Database System Rev Implement Rep"},{"key":"2026051407243720500_xvag117-B95","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.cardfail.2019.10.014","article-title":"Nutraceuticals in patients with heart failure: a systematic review","volume":"26","author":"Hopper","year":"2020","journal-title":"J Card Fail"},{"key":"2026051407243720500_xvag117-B96","volume-title":"Viagra Summary of Product Characteristics","author":"European Medicines Agency","year":"2023"},{"key":"2026051407243720500_xvag117-B97","volume-title":"Levitra Summary of Product Characteristics","author":"European Medicines Agency","year":"2021"},{"key":"2026051407243720500_xvag117-B98","volume-title":"Cialis Summary of Product Characteristics","author":"European Medicines Agency","year":"2021"},{"key":"2026051407243720500_xvag117-B99","volume-title":"Drug Approval Package: Cialis (tadalafil) Tablets","author":"U.S. Food and Drug Administration","year":"2004"},{"key":"2026051407243720500_xvag117-B100","author":"U.S. Food and Drug Administration"},{"key":"2026051407243720500_xvag117-B101","volume-title":"Revatio Summary of Product Characteristics","author":"European Medicines Agency","year":"2023"},{"key":"2026051407243720500_xvag117-B102","volume-title":"Adcirca Summary of Product Characteristics","author":"European Medicines Agency","year":"2008"},{"key":"2026051407243720500_xvag117-B103","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1385\/endo:23:2-3:135","article-title":"Therapy of ED: PDE-5 inhibitors","volume":"23","author":"Shabsigh","year":"2004","journal-title":"Endocrine"},{"key":"2026051407243720500_xvag117-B104","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1517\/14656566.2013.799665","article-title":"An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors","volume":"14","author":"Bruzziches","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"2026051407243720500_xvag117-B105","doi-asserted-by":"publisher","first-page":"905A","DOI":"10.1378\/chest.1113577","article-title":"ATHENA-1: hemodynamic improvements following the addition of ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension","volume":"140","author":"Oudiz","year":"2011","journal-title":"CHEST"},{"key":"2026051407243720500_xvag117-B106","doi-asserted-by":"publisher","first-page":"1602425","DOI":"10.1183\/13993003.02425-2016","article-title":"RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors","volume":"50","author":"Hoeper","year":"2017","journal-title":"Eur Respir J"},{"key":"2026051407243720500_xvag117-B107","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.rmed.2017.03.025","article-title":"Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1)","volume":"126","author":"Shapiro","year":"2017","journal-title":"Respir Med"},{"key":"2026051407243720500_xvag117-B108","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1016\/j.rmed.2016.11.001","article-title":"Rationale and study design of RESPITE: an open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors","volume":"122","author":"Hoeper","year":"2017","journal-title":"Respir Med"},{"key":"2026051407243720500_xvag117-B109","doi-asserted-by":"publisher","first-page":"H467","DOI":"10.1152\/ajpheart.1995.268.1.H467","article-title":"Effect of aging on nitric oxide-mediated penile erection in rats","volume":"268","author":"Garban","year":"1995","journal-title":"Am J Physiol"},{"key":"2026051407243720500_xvag117-B110","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/j.1743-6109.2006.00286.x","article-title":"Obesity, dyslipidemias and erectile dysfunction: a report of a subcommittee of the sexual medicine society of North America","volume":"3","author":"Mulhall","year":"2006","journal-title":"J Sex Med"},{"key":"2026051407243720500_xvag117-B111","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1745-7262.2008.00375.x","article-title":"Hypogonadism and erectile dysfunction: an overview","volume":"10","author":"Gurbuz","year":"2008","journal-title":"Asian J Androl"},{"key":"2026051407243720500_xvag117-B112","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1046\/j.1464-410x.2001.00065.x","article-title":"Nitric oxide-mediated corpus cavernosal smooth muscle relaxation is impaired in ageing and diabetes","volume":"87","author":"Cartledge","year":"2001","journal-title":"BJU Int"},{"key":"2026051407243720500_xvag117-B113","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/sj.ijir.3901494","article-title":"Endothelial dysfunction in diabetic erectile dysfunction","volume":"19","author":"Musicki","year":"2007","journal-title":"Int J Impot Res"},{"key":"2026051407243720500_xvag117-B114","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nm1175","article-title":"Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy","volume":"11","author":"Takimoto","year":"2005","journal-title":"Nat Med"},{"key":"2026051407243720500_xvag117-B115","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/ejhf.2527","article-title":"Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo-controlled multicentre trial","volume":"24","author":"Cooper","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026051407243720500_xvag117-B116","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1093\/eurheartj\/ehv336","article-title":"Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial","volume":"36","author":"Hoendermis","year":"2015","journal-title":"Eur Heart J"},{"key":"2026051407243720500_xvag117-B117","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1124\/mol.105.017608","article-title":"Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line","volume":"68","author":"Wunder","year":"2005","journal-title":"Mol Pharmacol"},{"key":"2026051407243720500_xvag117-B118","doi-asserted-by":"publisher","first-page":"16420","DOI":"10.1021\/acs.jmedchem.2c01267","article-title":"BAY-7081: a potent, selective, and orally bioavailable cyanopyridone-based PDE9A inhibitor","volume":"65","author":"Meibom","year":"2022","journal-title":"J Med Chem"},{"key":"2026051407243720500_xvag117-B119","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nature14332","article-title":"Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease","volume":"519","author":"Lee","year":"2015","journal-title":"Nature"},{"key":"2026051407243720500_xvag117-B120","doi-asserted-by":"publisher","first-page":"4226","DOI":"10.1182\/blood.V84.12.4226.bloodjournal84124226","article-title":"YC-1, a novel activator of platelet guanylate cyclase","volume":"84","author":"Ko","year":"1994","journal-title":"Blood"},{"key":"2026051407243720500_xvag117-B121","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/sj.bjp.0700982","article-title":"Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators","volume":"120","author":"M\u00fclsch","year":"1997","journal-title":"Br J Pharmacol"},{"key":"2026051407243720500_xvag117-B122","doi-asserted-by":"publisher","first-page":"5146","DOI":"10.1021\/acs.jmedchem.7b00449","article-title":"Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure","volume":"60","author":"Follmann","year":"2017","journal-title":"J Med Chem"},{"key":"2026051407243720500_xvag117-B123","first-page":"749","article-title":"Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","volume":"39","author":"Khaybullina","year":"2014","journal-title":"P T"},{"key":"2026051407243720500_xvag117-B124","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1093\/cvr\/cvac187","article-title":"Mechanisms of current therapeutic strategies for heart failure: more questions than answers?","volume":"118","author":"Khan","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026051407243720500_xvag117-B125","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jacc.2023.04.057","article-title":"Management of worsening heart failure with reduced ejection fraction: JACC focus seminar 3\/3","volume":"82","author":"Greene","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026051407243720500_xvag117-B126","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/0167-5273(95)02513-8","article-title":"Altered coronary endothelial function in a patient with asymptomatic left ventricular dysfunction","volume":"53","author":"Cannan","year":"1996","journal-title":"Int J Cardiol"},{"key":"2026051407243720500_xvag117-B127","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1161\/hypertensionaha.109.142190","article-title":"Arterial stiffness is regulated by nitric oxide and endothelium-derived hyperpolarizing factor during changes in blood flow in humans","volume":"55","author":"Bellien","year":"2010","journal-title":"Hypertension"},{"key":"2026051407243720500_xvag117-B128","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/0735-1097(89)90414-2","article-title":"Coronary vasomotion in response to sympathetic stimulation in humans: importance of the functional integrity of the endothelium","volume":"14","author":"Zeiher","year":"1989","journal-title":"J Am Coll Cardiol"},{"key":"2026051407243720500_xvag117-B129","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/eurheartj\/ehx565","article-title":"Retinal microvascular dysfunction in heart failure","volume":"39","author":"N\u00e4gele","year":"2018","journal-title":"Eur Heart J"},{"key":"2026051407243720500_xvag117-B130","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1002\/ejhf.1537","article-title":"Retinal microvascular dysfunction in patients with coronary artery disease with and without heart failure: a continuum?","volume":"21","author":"Barthelmes","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026051407243720500_xvag117-B131","first-page":"27","volume-title":"Contemporary Accounts in Drug Discovery and Development","author":"Follmann","year":"2021"},{"key":"2026051407243720500_xvag117-B132","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/bph.16230","article-title":"Red blood cell endothelial nitric oxide synthase: a major player in regulating cardiovascular health","volume":"183","author":"LoBue","year":"2026","journal-title":"Br J Pharmacol"},{"key":"2026051407243720500_xvag117-B133","doi-asserted-by":"publisher","DOI":"10.1172\/JCI167693","article-title":"Hypoxic erythrocytes mediate cardioprotection through activation of soluble guanylate cyclase and release of cyclic GMP","volume":"133","author":"Yang","year":"2023","journal-title":"J Clin Invest"},{"key":"2026051407243720500_xvag117-B134","doi-asserted-by":"publisher","first-page":"e345","DOI":"10.1016\/S2352-3026(24)00045-0","article-title":"Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1-2 trial","volume":"11","author":"Gladwin","year":"2024","journal-title":"Lancet Haematol"},{"key":"2026051407243720500_xvag117-B135","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044481","article-title":"The soluble guanylyl cyclase activator Bay 58-2667 selectively limits cardiomyocyte hypertrophy","volume":"7","author":"Irvine","year":"2012","journal-title":"PLoS One"},{"key":"2026051407243720500_xvag117-B136","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1161\/01.Hyp.0000241087.12492.47","article-title":"Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats","volume":"48","author":"Masuyama","year":"2006","journal-title":"Hypertension"},{"key":"2026051407243720500_xvag117-B137","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1111\/bph.15333","article-title":"Stimulation of soluble guanylyl cyclase (sGC) by riociguat attenuates heart failure and pathological cardiac remodelling","volume":"179","author":"R\u00fcdebusch","year":"2020","journal-title":"Br J Pharmacol"},{"key":"2026051407243720500_xvag117-B138","first-page":"A15553","article-title":"The sGC stimulator vericiguat improved outcome in a rodent model of heart failure with preserved ejection fraction (HFpEF)","volume":"138","author":"Mathar","year":"2018","journal-title":"Circulation"},{"key":"2026051407243720500_xvag117-B139","doi-asserted-by":"publisher","first-page":"5646","DOI":"10.1073\/pnas.1001360107","article-title":"Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes","volume":"107","author":"Lukowski","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026051407243720500_xvag117-B140","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s42003-023-04880-5","article-title":"It takes two to tango: cardiac fibroblast-derived NO-induced cGMP enters cardiac myocytes and increases cAMP by inhibiting PDE3","volume":"6","author":"Menges","year":"2023","journal-title":"Commun Biol"},{"key":"2026051407243720500_xvag117-B141","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2012.00128","article-title":"Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress","volume":"3","author":"Costell","year":"2012","journal-title":"Front Pharmacol"},{"key":"2026051407243720500_xvag117-B142","doi-asserted-by":"publisher","first-page":"10742484231185252","DOI":"10.1177\/10742484231185252","article-title":"Vericiguat reduces electrical and structural remodeling in a rabbit model of atrial fibrillation","volume":"28","author":"Lou","year":"2023","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2026051407243720500_xvag117-B143","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1124\/jpet.117.247429","article-title":"Pharmacological characterization of IW-1973, a novel soluble guanylate cyclase stimulator with extensive tissue distribution, antihypertensive, anti-inflammatory, and antifibrotic effects in preclinical models of disease","volume":"365","author":"Tobin","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"2026051407243720500_xvag117-B144","doi-asserted-by":"publisher","first-page":"F697","DOI":"10.1152\/ajprenal.00003.2020","article-title":"Praliciguat inhibits progression of diabetic nephropathy in ZSF1 rats and suppresses inflammation and apoptosis in human renal proximal tubular cells","volume":"319","author":"Liu","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026051407243720500_xvag117-B145","author":"European Medicines Agency"},{"key":"2026051407243720500_xvag117-B146","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1001\/jama.2015.15734","article-title":"Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial","volume":"314","author":"Gheorghiade","year":"2015","journal-title":"JAMA"},{"key":"2026051407243720500_xvag117-B147","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/ejhf.135","article-title":"Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES)","volume":"16","author":"Pieske","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026051407243720500_xvag117-B148","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"2026051407243720500_xvag117-B149","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jchf.2017.08.013","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator: the VICTORIA trial","volume":"6","author":"Armstrong","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026051407243720500_xvag117-B150","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(25)01665-4","article-title":"Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial","volume":"406","author":"Butler","year":"2025","journal-title":"Lancet"},{"key":"2026051407243720500_xvag117-B151","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jchf.2020.08.008","article-title":"N-terminal pro-B-type natriuretic peptide and clinical outcomes: vericiguat heart failure with reduced ejection fraction study","volume":"8","author":"Ezekowitz","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026051407243720500_xvag117-B152","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.jchf.2023.06.020","article-title":"Age, sex, and outcomes in heart failure with reduced EF: insights from the VICTORIA trial","volume":"11","author":"Lam","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026051407243720500_xvag117-B153","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jchf.2022.12.014","article-title":"Ejection fraction, biomarkers, and outcomes and impact of vericiguat on outcomes across EF in VICTORIA","volume":"11","author":"Butler","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026051407243720500_xvag117-B154","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/ejhf.2468","article-title":"Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction","volume":"24","author":"Saldarriaga","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026051407243720500_xvag117-B155","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.121.021094","article-title":"Blood pressure and safety events with vericiguat in the VICTORIA trial","volume":"10","author":"Lam","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026051407243720500_xvag117-B156","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/ejhf.2221","article-title":"Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial","volume":"23","author":"Voors","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026051407243720500_xvag117-B157","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.123.010599","article-title":"Background medical therapy and clinical outcomes from the VICTORIA trial","volume":"16","author":"Ezekowitz","year":"2023","journal-title":"Circ Heart Fail"},{"key":"2026051407243720500_xvag117-B158","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/ejhf.3179","article-title":"Diuretic use and outcomes in patients with heart failure with reduced ejection fraction: insights from the VICTORIA trial","volume":"26","author":"Ezekowitz","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026051407243720500_xvag117-B159","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1002\/ejhf.2608","article-title":"Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril\/valsartan: insights from the VICTORIA trial","volume":"24","author":"Senni","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026051407243720500_xvag117-B160","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40256-022-00557-2","article-title":"Vericiguat: a randomized, phase ib, placebo-controlled, double-blind, QTc interval study in patients with chronic coronary syndromes","volume":"23","author":"B\u00f6ttcher","year":"2023","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026051407243720500_xvag117-B161","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1093\/eurheartj\/ehaf655","article-title":"Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial","volume":"47","author":"Butler","year":"2025","journal-title":"Eur Heart J"},{"key":"2026051407243720500_xvag117-B162","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/S0140-6736(25)01682-4","article-title":"Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials","volume":"406","author":"Zannad","year":"2025","journal-title":"Lancet"},{"key":"2026051407243720500_xvag117-B163","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1002\/ejhf.3598","article-title":"Baseline characteristics of contemporary trial participants with heart failure and reduced ejection fraction: the VICTOR trial","volume":"27","author":"Saldarriaga","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026051407243720500_xvag117-B164","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.120.007132","article-title":"Risk profiles in heart failure: baseline, residual, worsening, and advanced heart failure risk","volume":"13","author":"Greene","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2026051407243720500_xvag117-B165","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/164_2018_197","article-title":"Soluble guanylate cyclase stimulators and activators","volume":"264","author":"Sandner","year":"2021","journal-title":"Handb Exp Pharmacol"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/advance-article-pdf\/doi\/10.1093\/eschf\/xvag117\/68164190\/xvag117.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/3\/xvag117\/68164190\/xvag117.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/3\/xvag117\/68164190\/xvag117.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:31:43Z","timestamp":1778758303000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/doi\/10.1093\/eschf\/xvag117\/8662940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":165,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,4,27]]},"published-print":{"date-parts":[[2026,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/eschf\/xvag117","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,4,27]]},"article-number":"xvag117"}}